Vendor, Austin, TX
MX3 Diagnostics, Inc.
UEI N8PKB5L9AZ49, CAGE 89US9
1 award and $131,374 obligated between September 27, 2024 and April 21, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| In-Vitro Diagnostic Substance ManufacturingNAICS 325413 | $131,374 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Hear when MX3 Diagnostics, Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
None of MX3 Diagnostics, Inc.'s contracts with a published end date ends in the next 19 months.
Competes with
Vendors selling in-vitro diagnostic substance manufacturing to Centers for Disease Control and Prevention, by dollars.
| Biosearch Technologies, Inc.Petaluma, CA | $1,243,300 |
| Seegene Usa, Inc.Irvine, CA | $179,440 |
| Hemostat Laboratories, Inc.Dixon, CA | $0 |
| Ab Diagnostic Systems GMBHBerlin | -$41,776 |
| Premier Medical USA Corp.Somerset, NJ | -$75,680 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75D30124C20303Definitive Contract, September 27, 2024, Full and Open Competition, 1 offers | CDC Office of Acquisition ServicesCenters for Disease Control and Prevention | Development and Demonstration of Mine Safety and Health TechnologyNAICS 325413, PSC AJ12 | $131,374 |
- Places of performance
- Texas
- Product and service codes
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Transactions
- 3 across 1 awards